Σλοβακία - Σλοβακικά - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

boehringer ingelheim animal health france scs, francúzsko - inj.

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcíny - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - flurbiprofén - 69 - otorhinolaryngologica

Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - flurbiprofén - 69 - otorhinolaryngologica

Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mapaex consumer healthcare (ireland) private limited, Írsko - flurbiprofén - 69 - otorhinolaryngologica

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

avimedical b.v. - itraconazole - antimycotics na systémové použitie, triazole deriváty, itraconazole - vtáčie - na liečbu aspergillosis a kandidózy v spoločník vtákov,.

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

intervet international bv - classical swine fever virus (csfv) -e2 podjednotky antigén - imunologické prístroje pre sviňovité - ošípané - aktívnej imunizácie ošípaných od veku 5 týždňov tehotenstva, aby sa zabránilo úmrtnosti a na zníženie klinických príznakov klasického moru ošípaných, ako aj na zníženie infekcie s a vylučovanie ssr oblasti vírus. nástup ochrany je 2 týždne. trvanie ochrany je 6 mesiacov.

Σλοβακία - Σλοβακικά - myHealthbox

bayer ag - dispergovateľné granule - iprovalicarb 40 g/kg; folpet 250 g/kg; fosetyl-al 500 g/kg

Σλοβακία - Σλοβακικά - myHealthbox

bayer ag - dispergovateľné granule - iprovalicarb 40 g/kg; folpet 250 g/kg; fosetyl-al 500 g/kg

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekurzorová bunková lymfoblastická leukémia-lymfóm - antineoplastické činidlá - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.